[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485179":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":49,"collaborators":51,"id":75,"slug":10,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":10,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who diagnosed as T2DM",null,"Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes",[13],"Procedure: Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination","Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination",[9],[21],{"name":22,"affiliation":23,"role":24},"Ling Li, Professor","Zhongda Hospital","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+8613951606816","lingli2022@hotmail.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Weixia Sun","+8615562596360","weixia19960914@163.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":10,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Zhongda Hospital, Medical School, Southeast University","RECRUITING","Nanjing","Jiangsu","China",{"type":42,"coordinates":43},"Point",[44,45],118.77778,32.06167,{"lat":45,"lon":44},[48],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52,54,56,59,61,63,65,67,69,71,73],{"name":23,"class":53},"OTHER",{"name":55,"class":53},"Suzhou Municipal Hospital",{"name":57,"class":58},"Suzhou Fifth People's Hospital","UNKNOWN",{"name":60,"class":58},"Xuzhou Mining Group General Hospital",{"name":62,"class":53},"Nantong First People's Hospital",{"name":64,"class":58},"Changzhou Second People's Hospital",{"name":66,"class":58},"Huaian Second People's Hospital",{"name":68,"class":58},"Huaian Hospital",{"name":70,"class":58},"Taizhou Jiangyan Traditional Chinese Medicine Hospital",{"name":72,"class":58},"Yangzhou Jiangdu People's Hospital",{"name":74,"class":58},"Huaian Xuyi County People's Hospital","100485179",false,"NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up","ALL","18 Years",{"count":84,"type":85},2900,"ESTIMATED","OBSERVATIONAL","In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[89,90],"Type 2 Diabetes Mellitus in Remission","Metabolic Associated Fatty Liver Disease",[92,93,94],"Type 2 diabetes mellitus","Metabolic associated fatty liver disease","ultrasound attenuation parameter","2022-10-24",{"date":97,"type":98},"2022-10-28","ACTUAL",{"date":100,"type":98},"2022-07-01",{"date":102,"type":85},"2027-06-01",{"name":5,"class":6},1]